Insider Transactions in Q2 2022 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
1,504
-12.15%
|
$6,016
$4.76 P/Share
|
|
Apr 29
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,505
+10.31%
|
$4,515
$3.84 P/Share
|
|
Apr 29
2022
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,504
+1.12%
|
$4,512
$3.84 P/Share
|
|
Apr 29
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,504
+10.84%
|
$4,512
$3.84 P/Share
|
|
Apr 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-15.62%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+19.61%
|
-
|
|
Apr 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-4.73%
|
$5,160
$6.07 P/Share
|
|
Apr 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,484
+6.44%
|
-
|
|
Apr 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-6.01%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+8.08%
|
-
|
|
Apr 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.83%
|
$31,314
$6.07 P/Share
|
|
Apr 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+6.76%
|
-
|
|
Apr 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-14.8%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+18.64%
|
-
|